Optimizing metoclopramide control of cisplatin-induced emesis

Area of Science:

• Pharmacology
• Oncology

Background:

• Cisplatin is a potent chemotherapy agent associated with significant nausea and vomiting.
• Metoclopramide is used to manage chemotherapy-induced emesis, but optimal dosing and efficacy require further definition.

Purpose of the Study:

• To establish a concentration-response relationship for metoclopramide in controlling cisplatin-induced emesis.
• To evaluate the impact of metoclopramide serum levels on emetic control and identify factors influencing response.

Main Methods:

• Serum metoclopramide levels were measured using high-pressure liquid chromatography.
• A specific intravenous metoclopramide regimen was administered and correlated with emetic episodes.
• Patient demographics, including age, were analyzed for their influence on drug levels and response.

Main Results:

• Serum metoclopramide levels exceeding 850 ng/mL were associated with complete (78%) or partial (18%) control of cisplatin-induced emesis.
• Patients with levels below 850 ng/mL experienced significantly less emetic control (p < 0.001).
• Elderly patients demonstrated increased sensitivity to metoclopramide, experiencing fewer emetic episodes at similar drug levels (p = 0.044).

Conclusions:

• A target serum concentration of >850 ng/mL for metoclopramide is recommended for optimal control of cisplatin-induced emesis.
• Dosage escalation up to 2.75 mg/kg can improve emetic control in non-responders without toxicity.
• Elderly patients may require lower doses due to increased sensitivity.